Addressing Pharmacy Challenges in Multiple Myeloma: Strategies for Overcoming Treatment Resistance

Addressing Pharmacy Challenges in Multiple Myeloma: Strategies for Overcoming Treatment Resistance

On-Demand Webcast
Faculty
 

Kirollos Hanna, PharmD, BCPS, BCOP
Oncology Pharmacy Manager
M Health Fairview - Maple Grove
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota
Intended Learners

This conference is designed for oncology and hematology pharmacists, pharmacy technicians, residents, interns, and pharmacy researchers.

Learning Objectives

After completing this activity, participants should be able to:

  • Describe the current standard of care for R/R MM as reflected in evidence-based guidelines
  • Implement pharmacist-guided strategies for overcoming treatment resistance in MM, including the use of optimal sequencing strategies, combination regimens, and AE management
  • Evaluate the importance of the multidisciplinary care team in MM shared decision-making practices and the delivery of patient-centric care 
Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity (Great Debates & Updates in Oncology Pharmacy 2021; July 22-24, 2021 or August 19-21, 2021) are not eligible to receive credit for this enduring webcast.

Release date: October 08, 2021
Expiration date: October 08, 2022
Estimated time to complete: 0.75 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

Jointly Accredited ProviderIn support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CPE

This activity is approved for .75 contact hour (0.075 CEU) of continuing pharmacy education (UAN JA0006201-0000-21-174-H01-P ).

This educational activity is a knowledge-based activity.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers,  Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.

Financial Disclosure and Conflicts of Interest

NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
  2. Any investigational, off-label, or non-FDA approved content or discussion

NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

  1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
  3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

FACULTY

The faculty has reported the following:

Kirollos Hanna, PharmD, BCPS, BCOP: Speakers’ Bureau–Seagen, Astellas, BeiGene, BMS, Exelixis, AbbVie; Consultant–Seagen, Astellas, Rigel; Advisory Board–Seagen, Astellas, AstraZeneca, GSK, Sanofi, G1 Therapeutics

Alexandre Chan has nothing to disclose in relation to this activity.

CLINICAL REVIEWER

Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, APh
Professor and Department Chair, Department of Clinical Pharmacy Practice
School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine
Irvine, CA

PLANNING COMMITTEE

NACCME planners and staff include Ms. Browne, Ms. Conforti, Ms. Duda, Ms. Hines, Ms. Johnson,  Mr. Robbin, Mr. Sellers, and Ms. Tong

No NACCME planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by educational grants from Oncopeptides and Sanofi Genzyme.